Share on StockTwits

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) have been given a consensus recommendation of “Hold” by the thirteen ratings firms that are currently covering the company, Analyst Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $41.70.

In other ISIS Pharmaceuticals news, CEO Stanley T. Crooke sold 16,000 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $30.53, for a total transaction of $488,480.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

ISIS has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday. They now have a $35.00 price target on the stock. Analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd.

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) traded up 0.34% on Friday, hitting $32.87. The stock had a trading volume of 532,123 shares. ISIS Pharmaceuticals has a 1-year low of $22.25 and a 1-year high of $62.66. The stock’s 50-day moving average is $32.30 and its 200-day moving average is $37.78. The company’s market cap is $3.870 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last released its earnings data on Monday, August 4th. The company reported ($0.10) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.12) by $0.02. The company had revenue of $57.08 million for the quarter, compared to the consensus estimate of $45.60 million. During the same quarter last year, the company posted ($0.09) earnings per share. ISIS Pharmaceuticals’s revenue was up 49.8% compared to the same quarter last year. On average, analysts predict that ISIS Pharmaceuticals will post $-0.73 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.